publication venue for
- BSCI-18. Identifying novel drivers of lung-to-brain metastasis through in vivo functional genomics. 3:iii5-iii5. 2021
- BSCI-19. Therapeutic intervention of lung-, breast-, and melanoma-brain metastasis. 3:iii5-iii5. 2021
- NGMA-5. An in vivo functional genomics screen to identify novel drivers of lung-to-brain metastasis. 3:ii5-ii5. 2021
- Identification of five important genes to predict glioblastoma subtypes. 3:vdab144. 2021
- 37. IN VIVO FUNCTIONAL GENOMIC SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS. 2:ii6-ii7. 2020
- 39. CHARACTERIZING NOVEL INHIBITORS OF BRAIN METASTASIS-INITIATING CELLS. 2:ii7-ii7. 2020
- 47. UNCOVERING A NOVEL ROLE FOR HLA-G IN BRAIN METASTASES. 2:ii9-ii9. 2020
- 60. IDEAL TREATMENT REGIMEN FOR PATIENTS WITH ≥1 BRAIN METASTASIS FROM PRIMARY NON-SMALL-CELL LUNG CANCER – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. 2:ii12-ii13. 2020
- Cervicomedullary hemangioblastoma treated with bevacizumab. 2:vdaa076. 2020
- BSCI-20. THERAPEUTIC TARGETING OF HLA-G IN BRAIN METASTASES. 1:i5-i5. 2019